←
BioCentury39,895 posts
BioCentury avatar

BioCentury

@BioCentury

The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis: bit.ly/4b1HDDu

◷ Joined December 2010▧ 885 Photos and videos
BioCentury avatar
BioCentury@BioCentury·20h

Isomorphic raises $5B in the largest biotech venture round yet. AI drug design company’s series C round comes just six months after a $2.1B round, and before a program has entered the clinic. buff.ly/Tw7bj66

BioCentury avatar
BioCentury@BioCentury·21h

Biopharmas should invest in tools to close biological AI’s data gaps — a Perspective by BioCentury's Lindsay Martin. Shared initiatives can set the foundation, but biopharmas should invest in measurements that address gaps relevant to their portfolios buff.ly/Rc9YTRM

BioCentury avatar
BioCentury@BioCentury·Nov 17

FDA held Summit to its survival bar for ivonescimab in EGFR-mutant lung cancer. The pivotal trial met its PFS endpoint but missed on overall survival. Longer follow-up showed a similar survival trend favoring ivonescimab in Western and Asian patients. buff.ly/264hJ3j

BioCentury avatar
BioCentury@BioCentury·Nov 12

Skape Bio: Designing miniproteins for GPCR pockets antibodies struggle to reach. Baker lab spinout combines de novo design with screening in human cells to develop GPCR agonists and antagonists buff.ly/zLR3oE3